Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Tingle,,,tingle,,tingle,,,,ummmm!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(111)
•••
Comment by prophetoffactzon Jul 22, 2022 2:10pm
157 Views
Post# 34843954

RE:Tingle,,,tingle,,tingle,,,,ummmm!

RE:Tingle,,,tingle,,tingle,,,,ummmm!Q4 for the inititation of the GBS clinical trial and that followed by a NASDAQ uplist in Q4 according to the presentation last month. More than one party was interested in xB3 cancer assets as of the presentation. That could leave enough time to conclude a deal for the cancer assets. That could help rebuild confidence in xB3 ahead of NASDAQ and support the financing. The three pipeline programs were also still being developed. It would be nice to see the data finally to support xB3 after so many delays. An Oxyrane deal could help support BTI's xB3 initiative given the importance of LSDs. Chiesi expects its FDA submission for Fabry by the end of this year with potential approval in Europe and in the US in th first half of 2023 helping make it an important player in LSD.     
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities